Biomarker validation and testing

Molecular Oncology

Volumn 9, Issue 5, 2015, Pages 960-966

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Level of evidence; Tumor biomarkers; Validation

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ASSAY; CANCER PROGNOSIS; CANCER SCREENING; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VALIDITY; METABOLISM; NEOPLASMS; VALIDATION STUDY;

BIOMARKERS, TUMOR; HUMANS; NEOPLASMS;

EID: 84928572844     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.10.004     Document Type: Review

References (19)

1. AJCC Breast. AJCC Staging Manual 2010, Springer, New York, Dordrecht, Heidelberg, London. Seventh ed. S.B. Edge, D.R. Byrd, C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
2. Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. Plos Med. 2012, 9:e1001216.
3. Andre F., McShane L.M., Michiels S., Ransohoff D.F., Altman D.G., Reis-Filho J.S., Hayes D.F., Pusztai L. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 2011, 8:171-176.
4. Freidlin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: design issues. J.Natl. Cancer Inst. 2010, 102:152-160.
5. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., Fitzgibbons P.L., Francis G., Goldstein N.S., Hayes M., Hicks D.G., Lester S., Love R., Mangu P.B., McShane L., Miller K., Osborne C.K., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz J.N., Sweep F.C., Taube S., Torlakovic E.E., Valenstein P., Viale G., Visscher D., Wheeler T., Williams R.B., Wittliff J.L., Wolff A.C. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J.Clin. Oncol. 2010, 28:2784-2795.
6. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., Fitzgibbons P.L., Francis G., Goldstein N.S., Hayes M., Hicks D.G., Lester S., Love R., Mangu P.B., McShane L., Miller K., Osborne C.K., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz J.N., Sweep F.C., Taube S., Torlakovic E.E., Valenstein P., Viale G., Visscher D., Wheeler T., Williams R.B., Wittliff J.L., Wolff A.C. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 2010, 134:e48-e72.
7. Hayes D.F., Allen J., Compton C., Gustavsen G., Leonard D.G., McCormack R., Newcomer L., Pothier K., Ransohoff D., Schilsky R.L., Sigal E., Taube S.E., Tunis S.R. Breaking a vicious cycle. Sci. Transl. Med. 2013, 5. 196cm196.
8. Hayes D.F., Bast R.C., Desch C.E., Fritsche H., Kemeny N.E., Jessup J.M., Locker G.Y., Macdonald J.S., Mennel R.G., Norton L., Ravdin P., Taube S., Winn R.J. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J.Natl. Cancer Inst. 1996, 88:1456-1466.
9. Henry N.L., Hayes D.F. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006, 11:541-552.
10. Institute of Medicine Evolution of Translational Omics: Lessons Learned and the Path Forward 2012, The National Academies Press, Washington, D.C.
11. McShane L.M., Hayes D.F. Publication of tumor marker research results: the necessity for complete and transparent reporting. J.Clin. Oncol. 2012, 30:4223-4232.
12. Moher D., Schulz K.F., Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann. Intern. Med. 2001, 134:657-662.
13. Moore H.M., Kelly A., McShane L.M., Vaught J. Biospecimen reporting for improved study quality (BRISQ). Clin. Chim. Acta 2012, 413:1305.
14. Sargent D.J., Conley B.A., Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J.Clin. Oncol. 2005, 23:2020-2027.
15. Schilsky R.L. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J.Clin. Oncol. 2009, 27:3725-3730.
16. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J.Natl. Cancer Inst. 2009, 101:1446-1452.
17. Teutsch S.M., Bradley L.A., Palomaki G.E., Haddow J.E., Piper M., Calonge N., Dotson W.D., Douglas M.P., Berg A.O. The evaluation of genomic applications inpractice and prevention (EGAPP) initiative: methods ofthe EGAPP working group. Genet. Med. 2009, 11:3-14.
18. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline update. Arch. Pathol. Lab. Med. 2013.
19. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J.Clin. Oncol. 2013, 31:3997-4013.